Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries AC Immune S.A. (NQ: ACIU ) 3.000 +0.160 (+5.63%) Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 73,043 Open 2.860 Bid (Size) 2.860 (2) Ask (Size) 3.000 (10) Prev. Close 2.840 Today's Range 2.850 - 3.000 52wk Range 2.250 - 5.140 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Granite Point Mortgage Trust Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket September 23, 2024 Via Benzinga AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer’s Disease September 17, 2024 From AC Immune SA Via GlobeNewswire Performance YTD -36.03% -36.03% 1 Month -11.50% -11.50% 3 Month -14.04% -14.04% 6 Month +25.00% +25.00% 1 Year +10.29% +10.29% More News Read More AC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative Conditions August 28, 2024 From AC Immune SA Via GlobeNewswire AC Immune Reports Second Quarter 2024 Financial Results and Provides a Corporate Update August 06, 2024 From AC Immune SA Via GlobeNewswire AC Immune Unveils Novel Therapeutic Antibody Drug Conjugate (ADC) Technology for Improved Efficacy in Neurodegenerative Diseases at AAIC 2024 July 31, 2024 From AC Immune SA Via GlobeNewswire AC Immune’s ACI-35.030 (now “JNJ-2056”) Granted FDA Fast Track Designation for Alzheimer’s Disease July 25, 2024 From AC Immune SA Via GlobeNewswire AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024 July 16, 2024 From AC Immune SA Via GlobeNewswire RH Posts Mixed Q1 Results, Joins MSC Industrial Direct And Other Big Stocks Moving Lower In Friday's Pre-Market Session June 14, 2024 Via Benzinga Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session May 31, 2024 Via Benzinga Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday May 31, 2024 Via Benzinga AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 May 28, 2024 From AC Immune SA Via GlobeNewswire e.l.f. Beauty Posts Upbeat Earnings, Joins Nvidia, LiveRamp Holdings, Borr Drilling And Other Big Stocks Moving Higher On Thursday May 23, 2024 Via Benzinga DLocal, Allogene Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session May 15, 2024 Via Benzinga ACIU Stock Earnings: AC Immune Misses EPS for Q1 2024 May 13, 2024 Via InvestorPlace Gold Down Over 1%; AC Immune Shares Spike Higher May 13, 2024 Via Benzinga Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday? May 13, 2024 Via Benzinga Why Akoustis Technologies Shares Are Trading Lower By Around 18%? Here Are Other Stocks Moving In Monday's Mid-Day Session May 13, 2024 Via Benzinga Crude Oil Surges Over 1%; Amprius Technologies Shares Plunge May 13, 2024 Via Benzinga Exposures Fossil Fuels Why Is TransCode Therapeutics (RNAZ) Stock Down 14% Today? May 13, 2024 Via InvestorPlace Why Is Safe & Green Development (SGD) Stock Down 5% Today? May 13, 2024 Via InvestorPlace Topics Regulatory Compliance Exposures Legal Regulatory Why Is AC Immune (ACIU) Stock Up 45% Today? May 13, 2024 Via InvestorPlace Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday May 13, 2024 Via InvestorPlace AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update May 13, 2024 From AC Immune SA Via GlobeNewswire AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease May 13, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease May 13, 2024 From AC Immune SA Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
